Literature DB >> 9559819

Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.

M A Visalli1, M R Jacobs, P C Appelbaum.   

Abstract

A total of 124 Pseudomonas aeruginosa strains were tested for synergy between levofloxacin and cefpirome, ceftazidime, gentamicin, and meropenem. Checkerboards yielded synergistic fractional inhibitory concentration (FIC) indices (< or =0.5) with 25 of 496 possible combinations. All other FIC indices were >0.5 to 2 (additive or indifferent), with no antagonism. Time-kill studies with 12 strains showed that levofloxacin (0.06 to 0.5 microg/ml) was synergistic with cefpirome, ceftazidime, gentamicin, and meropenem in 10, 9, 4, and 11 strains, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559819      PMCID: PMC105578          DOI: 10.1128/AAC.42.4.953

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.

Authors:  A F Cheng; T K Ling; A W Lam; K S Fung; R Wise
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

5.  Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System.

Authors:  D R Burwen; S N Banerjee; R P Gaynes
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

Review 6.  The aminoglycosides.

Authors:  R S Edson; C L Terrell
Journal:  Mayo Clin Proc       Date:  1991-11       Impact factor: 7.616

Review 7.  Meropenem: a microbiological overview.

Authors:  J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

Review 8.  The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens.

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

9.  Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.

Authors:  P Gargalianos; B A Oppenheim; P Skepastianos; D M Livermore; R J Williams
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

10.  Future trends in aminoglycoside therapy.

Authors:  S Levin; P H Karakusis
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

View more
  15 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

3.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

5.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 6.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

8.  Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.

Authors:  Federico Pea; Federica Pavan; Ennio Nascimben; Claudio Benetton; Pier Giorgio Scotton; Alberto Vaglia; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

Review 10.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.